DCP-LA FR236924|cas:28399-31-7|西域试剂

DCP-LA FR236924,98.0%

产品编号：Bellancom-108599| CAS NO：28399-31-7| 分子式：C₂₀H₃₆O₂| 分子量：308.50

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-108599	￥900.00	杭州北京（现货）
Bellancom-108599	￥1500.00	杭州北京（现货）
Bellancom-108599	￥2100.00	杭州北京（现货）
Bellancom-108599	￥4200.00	杭州北京（现货）
Bellancom-108599	￥7200.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

DCP-LA FR236924

产品介绍

DCP-LA (FR236924) 是一种亚油酸衍生物，选择性地激活 PKCε。DCP-LA 能够刺激 AMP 受体胞吐，并抑制蛋白磷酸酶-1 (PP-1) 和激活 Ca(²⁺)/钙调素依赖性蛋白激酶 II (CaMKII)。DCP-LA 能够抑制 caspase-3/-9 激活，以保护神经元免受到氧化应激诱导的细胞凋亡的影响。

生物活性

DCP-LA (FR236924), a linoleic acid derivative, selectively and directly activates PKCε. DCP-LA activates Ca(²⁺)/calmodulin-dependent protein kinase II (CaMKII) and inhibits protein phosphatase-1 (PP-1) to stimulate AMPA receptor exocytosis. DCP-LA inhibits activation of caspase-3/-9 and protects neurons at least in part from oxidative stress-induced apoptosis.

体外研究

DCP-LA (100 nM; 15 min) activates cytosolic PKCε by binding to the phosphatidylserine binding/associating sites Arg50 and Ile89, without translocation towards the cell surface in PL-12 cells.
DCP-LA (10, 100, 100 nM; 10 min; 35 ℃) activates CaMKII and inhibits PP-1 in rat hippocampal neurons.
DCP-LA (100 nM; 20 min) increases expression of the receptors on the plasma membrane, responsible for potentiate AMPA receptor responses in rat hippocampal slices.
DCP-LA (100 nM; 10 min) results facilitation of hippocampal synaptic transmission.
DCP-LA (100 nM; 24 h) prevents the Sodium nitroprusside (SNP, HY-10219) effect and rescues neurons from SNP-induced degradation.
DCP-LA (100 nM; 12 h) abolishes the caspase-3/9 activation induced by Sodium nitroprusside (SNP, HY-10219) (1 mM).

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay

Cell Line:	Rat cerebral cortical neurons
Concentration:	100 nM
Incubation Time:	24 hours; accompanied with 1 mM Sodium nitroprusside (SNP)
Result:	Prevented SNP-induced neuronal cell death.

体内研究
(In Vivo)

DCP-LA (1 mg/kg; p.o.; once daily; 7 d) exhibits a protective effect against ischemic brain damage, decreasing cerebral cortical defect due to middle cerebral artery (MCA) occlusion in mouse model.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Middle cerebral artery (MCA) occlusion in mouse model (male CB-17 mice, 5-8 weeks old)
Dosage:	1 mg/kg
Administration:	Oral gavage; once daily for 7 days; sacrificed mice on days 28
Result:	Significantly diminished degraded area due to cerebral infarction, with the rescued area reaching 82%.

体内研究

DCP-LA (1 mg/kg; p.o.; once daily; 7 d) exhibits a protective effect against ischemic brain damage, decreasing cerebral cortical defect due to middle cerebral artery (MCA) occlusion in mouse model.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Middle cerebral artery (MCA) occlusion in mouse model (male CB-17 mice, 5-8 weeks old)
Dosage:	1 mg/kg
Administration:	Oral gavage; once daily for 7 days; sacrificed mice on days 28
Result:	Significantly diminished degraded area due to cerebral infarction, with the rescued area reaching 82%.

体内研究

DCP-LA (1 mg/kg; p.o.; once daily; 7 d) exhibits a protective effect against ischemic brain damage, decreasing cerebral cortical defect due to middle cerebral artery (MCA) occlusion in mouse model.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Middle cerebral artery (MCA) occlusion in mouse model (male CB-17 mice, 5-8 weeks old)
Dosage:	1 mg/kg
Administration:	Oral gavage; once daily for 7 days; sacrificed mice on days 28
Result:	Significantly diminished degraded area due to cerebral infarction, with the rescued area reaching 82%.

性状

Liquid

溶解性数据

In Vitro:

DMSO : 5 mg/mL (16.21 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	3.2415 mL	16.2075 mL	32.4149 mL
5 mM	0.6483 mL	3.2415 mL	6.4830 mL
10 mM	0.3241 mL	1.6207 mL	3.2415 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 0.5 mg/mL (1.62 mM); Clear solution

此方案可获得 ≥ 0.5 mg/mL (1.62 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 5.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: 0.5 mg/mL (1.62 mM); Suspended solution; Need ultrasonic

此方案可获得 0.5 mg/mL (1.62 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。
以 1 mL 工作液为例，取 100 μL 5.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
3.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 0.5 mg/mL (1.62 mM); Clear solution

此方案可获得 ≥ 0.5 mg/mL (1.62 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 5.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。